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Abstract
Essential hypertension isa commonmultifactorial heritable conditioninwhich increasedsympatheticoutflow fromthe central
nervous system is involved in the elevation in blood pressure (BP), as well as the exaggerated morning surge in BP that is a risk
factor for myocardial infarction and stroke in hypertensive patients. The Schlager BPH/2J mouse is a genetic model of
hypertension in which increased sympathetic outflow from the hypothalamus has an important etiological role in the
elevation of BP. Schlager hypertensive mice exhibit a large variation in BP between the active and inactive periods of the day,
and also show a morning surge in BP. To investigate the genes responsible for the circadian variation in BP in hypertension,
hypothalamic tissue was collected from BPH/2J and normotensive BPN/3J mice at the ‘peak’ (n=12) and ‘trough’ (n=6) of
diurnal BP. Using Affymetrix GeneChipH Mouse Gene 1.0 ST Arrays, validation by quantitative real-time PCR and a statistical
method that adjusted for clock genes, we identified 212 hypothalamic genes whose expression differed between ‘peak’ and
‘trough’ BP in the hypertensive strain. These included genes with known roles in BP regulation, such as vasopressin, oxytocin
and thyrotropin releasing hormone, as well as genes not recognized previously as regulators of BP, including chemokine (C-C
motif) ligand 19, hypocretin and zinc finger and BTB domain containing 16. Gene ontology analysis showed an enrichment of
terms for inflammatory response, mitochondrial proton-transporting ATP synthase complex, structural constituent of
ribosome, amongst others. In conclusion, we have identified genes whose expression differs between the peak and trough of
24-hour circadian BP in BPH/2J mice, pointing to mechanisms responsible for diurnal variation in BP. The findings may assist in
the elucidation of the mechanism for the morning surge in BP in essential hypertension.
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Introduction
Essential hypertension is a common [1] multifactorial condition
involving the influence of numerous, mostly unidentified genes,
generally thought to have small effects on blood pressure (BP) [2].
Essential hypertensivepatients display an exaggerated increase in BP
levels in the morning, referred to as the morning BP surge [3]. The
basis of this phenomenon is not well understood. The morning surge
is known to increase risk of cardiovascular events [4]. The
identification of the mechanisms responsible for circadian variations
inBP,particularlyinhypertensivepatients,shouldassistinthedesign
of new strategies for resolving the pathophysiology of this condition.
In both animal models and humans, there is increasing evidence
that the sympathetic nervous system (SNS) is involved in the
development and progression of hypertension [5]. The causes of
the sympathetic activation are, however, still unclear. The SNS is
also a key regulator of the morning BP surge phenomenon [6], and
the use of drugs which target the SNS are effective in reducing it
[7]. It was reported that acute sympathetic blockade decreases BP
in the Schlager BPH/2J hypertensive mouse strain [8], consistent
with involvement of the SNS in this genetic model of hypertension.
The hypertensive strain presents a very distinctive circadian
variation of BP similar to humans with essential hypertension.
During the active phase average mean arterial pressure (MAP) of
the BPH/2J strain is 30 mm Hg higher than in the normotensive
(BPN/3J) strain, and during the inactive phase is 16 mm Hg
higher (Figure 1) [8]. Moreover, during the active phase,
hypothalamic regions in the Schlager hypertensive mouse,
specifically the paraventricular nucleus (PVN) and dorsomedial
hypothalamus (DMH), exhibit higher neuronal activation than is
seen in the BPN/3J [8]. Importantly, the PVN and DMH are
brain regions known to be critical for the regulation of
cardiovascular autonomic function [9,10]. These hypothalamic
regions are therefore likely to be important for the exaggerated
circadian variation of BP in BPH/2J mice.
The aim of the present study was to identify, at the genome-
wide level, the genes and imputed mechanisms in the hypothal-
amus that contribute to the higher BP in the active (dark phase)
period in the Schlager hypertensive mouse. Although the
hypothalamus is known to be a major regulator of the normal
circadian rhythm and level of BP, our objective was not to identify
clock genes associated with normal changes of BP. Therefore we
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19203used a statistical analysis which sought to eliminate clock genes by
first comparing samples from BPH/2J to those for the control
collected at the same time, i.e., prior to comparing hypertensive
samples collected at ‘peak’ or ‘trough’ BP.
Methods
Ethics Statement
This study was approved by the Alfred Hospital Animal Ethical
Review Committee (Permit number: E/0866/2009/B).
Samples and tissue collection
Radiotelemetry studies by ourselves [8,11], as well as tail-cuff
measurements [12], have shown that BPH/2J hypertensive mice
have high overall MAP of 12762 mm Hg [8], while BPN/3J mice
have normal overall MAP of 11161 mm Hg [8]. Moreover, the
hypertensive strain shows an exaggerated day-night difference
(1762 mm Hg) compared to the normotensive strain (661m m
Hg) and normal BP C57/B16 mice (862 mm Hg) [8].
In the present study, adult (19–26 week old) BPH/2J mice and
age-matched BPN/2J mice (n=3/group, ‘trough’ BP) were killed
Figure 1. Circadian variation of blood pressure in the Schlager hypertensive and normotensive strains. Hourly averaged data showing
the circadian variation of mean arterial pressure (mm Hg) during the active (night; outer black panels) and inactive (day; middle white panel) phases
in 23 week-old BPN/3J and BPH/2J mice. Values are mean 6 SEM for comparisons between strains across the entire 24 hours. Black arrow indicates
when ‘trough’ BP samples were collected, and gray arrow indicates when ‘peak’ BP samples were collected. Adapted from Davern et al. [8].
doi:10.1371/journal.pone.0019203.g001
Table 1. Selected genes differentially expressed at ‘peak’ BP in the Schlager hypertensive mouse compared to ‘trough’ BP
samples, showing primers, qPCR conditions and adjusted fold difference (aFD) values for both qPCR and microarray experiments.
Official gene
symbol
GenBank
Accession # Primer Sequence (59 39) Concentration
Annealing
temperature
aFD value
(qPCR)
aFD value
(arrays)
Actb NM_007393.3 F: AACGGCTCCGGCATGTGCAAAG,
R: ATCACACCCTGGTGCCTAGGGCG
200 nM 55–61uC– –
Avp NM_009732.1 F: CTGCTGGCCTTCTCCTCCGCC,
R: CGGGCCGCAGGGGAGACAC
200 nM 58uC 7.59 2.30
Ccl19 NM_011888.2 F: ACCTCCAGACCAGCCCTGGGT,
R: TGGTGCTGTTGCCTTTGTTCTTGGC
200 nM 61uC 1.36 1.72
Hcrt NM_010410.2 F: TGGGTATTTGGACCACTGCACTGA,
R: CAGGGAACCTTTGTAGAAGGAAAGTTC
200 nM 55uC 6.12 2.05
Oxt NM_011025.3 F: TCACCTACAGCGGATCTCAGACTGA,
R: CCCAGGGGGCAGTTCTGGATGTA
200 nM 55uC 18.9 3.37
Trh NM_009426.2 F: CCAGGAGGAAGGTGCTGTGAC,
R: GTGATCCAGGAATCTAAGGCAGC
200 nM 55uC 8.46 2.10
Zbtb16 NM_001033324.2 F: GTCCGGTCCGGTCCCCTC,
R: GGGCTCAGGCATGGGGCTCT
200 nM 58uC 3.75 1.61
F: forward primer, R: reverse primer. Values represent mean of the adjusted fold difference (aFD) statistic between ‘peak’ and ‘trough’ samples. Positive aFD values
indicate higher expression in the hypertensive group samples collected in the active period, and negative aFD values indicate higher expression in the hypertensive
group samples collected in the inactive period.
doi:10.1371/journal.pone.0019203.t001
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period, when the MAP levels of the BPH/2J and BPN/3J models
differ by only 16 mm Hg [8]. BPH/2J mice and age-matched
BPN/2J mice (n=6/group, ‘peak’ BP) were killed in the same way
at the peak of the circadian variation in BP, when average MAP
difference between the strains was maximal (30 mm Hg) [8].
Figure 1 indicates the times when the mice were killed. The PVN
and DMH, as defined by known anatomical boundaries [13], were
removed immediately after death by PJD, who has extensive
experience in dissecting PVN and DMH regions of the
hypothalamus [8,13]. The tissue was first preserved in dry ice
and later transferred to a –80uC freezer and used for microarray
experiments within 7 days. Each animal was considered an
individual sample and no pooling was performed.
RNA extraction and quality and quantity assessment
The RNeasy kit (Qiagen) was used for RNA extraction and was
performed according to the manufacturer’s recommendations.
RNA quality was confirmed based on a RNA integrity number
(RIN) higher than 8 by use of an electrophoresis bioanalyzer (2100
Agilent Bioanalyzer). This step was carried out by the Ramaciotti
Centre for Gene Function Analysis, University of New South
Wales, Sydney, Australia. Quantification involved spectrophotom-
etry (NanoDropH ND-100 spectrophotometer, Thermo Scientific)
in the Laboratory at the University of Sydney.
Microarray experiments and analyses
mRNA was converted to single-stranded DNA, labeled and
hybridized to GeneChipH Mouse Gene 1.0 ST Arrays (Affyme-
trix), which analyze 28,869 gene transcripts using 764,885 probe
sets (on average 27 probes per gene), all according to the
manufacturer’s instructions, and with the assistance of the
Ramaciotti Centre. Samples were normalized using robust-
multi-array analysis (RMA) [14]. The data set obtained has been
deposited in the NCBI Gene Expression Omnibus database
according to MIAME guidelines with series accession number
GSE26007.
Direct comparison of differentially expressed genes between
‘trough’ and ‘peak’ BP samples would normally identify many
‘‘clock’’ genes that are of limited interest. Thus gene expression
related to the circadian differences in hypertension were found by
first adjusting for the circadian differences from BPN/3J. This
analysis was performed using the adjusted fold difference (aFD)
statistics we described previously [15]. Differentially expressed
genes were selected based on an absolute aFD value exceeding 1.5,
where positive aFD values indicate higher expression at ‘peak’ BP
and negative aFD values indicate higher expression ‘trough’ BP in
the Schlager hypertensive mouse. Hierarchical clustering using
Euclidean distance was performed with TMeV 4.5 [16].
The Gene Ontology (GO) database [17] was used to further
interpret the differentially expressed gene data set and to identify
over-represented functional groups of genes. A hypergeometric
test using GOstats [18] was used to determine if particular GO
terms were more significantly over or under represented in the
differentially expressed gene list than the gene list of the entire
array. Up-regulated and down-regulated genes were examined
separately. A gene set test (GST), implemented via the Limma
package [19], was used to highlight pathways that are differentially
expressed as a set, for all genes ranked via P values, and adjusted
by false discovery rate (FDR). In both the GO and GST analyses,
ontologies with an overall probe count of less than 5 were
removed.
Using the ‘Core Analysis’ function in the Ingenuity Pathway
Analysis (IPA, IngenuityH Systems, www.ingenuity.com) applica-
tion, molecular networks were built. Briefly, a data set containing
differentially expressed genes and respective fold differences were
uploaded into the application. These genes were then correlated
based on previous association between genes or proteins and
known functional roles of genes. The biological relationship
between two genes, represented as nodes, is shown as a line. Nodes
with different shapes indicate different functional class.
Semi-quantitative real-time PCR (qPCR)
qPCR was conducted to confirm the results for genes whose
functions were considered to be of possible interest in hyperten-
sion. The first-strand complementary synthesis reaction was
performed using the SuperScriptH VILO
TM cDNA Synthesis Kit
(Invitrogen). Amplification reactions used the EXPRESS SYBRH
GreenER
TM qPCR reagent system (Invitrogen) in a Light Cycler
480 qPCR machine (Roche). Primers were specifically designed
around the most differentially expressed probe in the transcript
cluster of each gene using Primer3 [20]. Where possible, primers
were designed to flank an exon-exon junction. Primer and
conditions used are indicated in Table 1. Samples were run in
duplicate. The specificity of the qPCR was ensured by melting
curve analysis and agarose gel electrophoresis (data not shown).
The b-actin mRNA (Actb) was used as the reference gene. The
comparative CT statistical method was used to assess significance
[21].
The aFD value was used to compare ‘trough’ and ‘peak’ BP
hypertensive samples. Normotensive samples collected at the
same times of 24 h BP variation as for the hypertensive
mice were used as controls. The statistical package SPSS for
Windows, Release 17.0, was used to compare normotensive
and hypertensive groups collected at both ‘peak’ and ‘trough’ BP
by one-way analysis of variance (ANOVA), followed by correction
for multiple testing using the Bonferroni post-hoc test, to
determine significance of differences between the groups. Signif-
icance was set at P,0.05.
Results
Hierarchical clustering showed that hypertensive and normo-
tensive samples collected at ‘peak’ or ‘trough’ BP have distinctive
patterns of gene expression (Figure 2). Using an aFD value $1.5,
212 well-annotated genes were identified between ‘trough’ and
‘peak’ BP samples of BPH/2J hypertensive mice. Table 1
summarizes the data for selected genes that we validated by
qPCR (for complete information please see Table S1). aFD values
from qPCR and microarray experiments are shown in Table 1
and Figure 3.
ANOVA (Figure 4) showed that the hypertensive strain has an
impaired response during the inactive period for the gene oxytocin
(Oxt). Moreover the expression of the genes chemokine (C-C motif)
Figure 2. Hierarchical clustering comparing hypothalamic gene expression in active and inactive Schlager hypertensive and
normotensive strains. Hierarchical clustering using Euclidean distance comparing the gene expression in the hypothalamus of ‘peak’ (left column,
active period) versus ‘trough’ (right column, inactive period) hypertensive BPH/2J mice and age-matched normotensive BPN/3J samples. Distinctive
patterns can be observed. Clusters of genes of similar biological relevance are indicated. Red depicts genes upregulated and green those
downregulated.
doi:10.1371/journal.pone.0019203.g002
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during the active period in the BPH/2J than in the same strain
during the inactive period or than the BPN/3J strain during the
same period.
At ‘peak’ BP, GO analysis showed an enrichment of terms such
as neuropeptide signaling pathway, defense response, chemokine
and cytokine activity, immune system development (which could
indicate an increase in inflammation), mitochondrial proton-
transporting ATP synthase complex, and many terms related to
structural constituent of ribosome, among others (see Table S2). At
‘peak’ BP in the BPH/2J hypertensive mice, the GST indicated an
over-representation of G-protein coupled receptor protein signal-
ing pathway, transcription factor and regulator activity, and
cytokine activity, and a down-representation of chromatin
modification, assembly or disassembly and helicase activity,
amongst others (see Table S3).
In silico molecular networks among the genes identified are
shown in Figure 5. The most significant network highlighted
cardiovascular disease and molecular transport (Figure 5A),
consistent with a genetic component influencing circadian BP
variation and thereby cardiovascular disease in this model.
Discussion
This study is, to our knowledge, the first to evaluate genome-
wide gene expression signatures in the hypothalamus during
circadian variation of BP in the Schlager hypertensive mouse, a
model that exhibits a similar morning BP surge as seen in human
essential hypertension. The main findings suggest an involvement
of arginine vasopressin (Avp), Oxt and thyrotropin releasing
hormone (Trh), which are known genes in the regulation of BP.
Our study proposes new candidates genes for the arousal-
associated exaggerated circadian changes in BP in the BPH/2J
mouse, such as Ccl19, Hcrt, and zinc finger and BTB domain
containing 16 (Zbtb16). Consistent with the relevance of the BPH/
2J strain to the morning BP surge in human hypertension, the
present study has identified the genes for aldehyde dehydrogenase
family 1 subfamily A2 (Aldh1a2) and solute carrier family 8
Figure 4. qPCR results for genes differentially expressed in the hypothalamus at ‘peak’ and ‘trough’ time-points in the Schlager
hypertensive and normotensive strains. Shown is relative mRNA abundance for the genes Avp, Ccl19, Hcrt, Oxt, Trh and Zbtb16. Vertical bars
show standard error of the mean; *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0019203.g004
Figure 3. Validation of the aFD values using qPCR, showing results for the genes (A) Avp, Ccl19, Hcrt, and (B) Oxt, Trh and Zbtb16. This
analysis took into account qPCR confirmation and the interaction between qPCR (top plots) and microarray results (bottom plots) with blood
pressure (shown at the left of each plot is ‘trough’, and at the right is ‘peak’).
doi:10.1371/journal.pone.0019203.g003
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genes identified in genome-wide association studies of hyperten-
sion [22,23]. All of these findings together, suggest indirect
dysregulation of the angiotensinergic system and inflammation,
amongst others, as influencing exaggerated circadian changes in
BP in the Schlager hypertensive mouse.
Genes for catecholamine biosynthesis were not amongst those we
identified. Nor were genes of the angiotensinergic system itself. On
the other hand, the gene for Zbtb16 (aFD=1.6, also known as Plzf)
can interact with and regulate components of the renin-angiotensin
system. Following treatment with angiotensin II (Ang II), Zbtb16
binds to Ang II type 2 receptor (AGTR2) located in the plasma
membrane, and then both internalize together [24]. Similarly,
internalization is observed when prorenin/renin binds to the
(pro)renin receptor, Atp6ba2 [25,26]. Such binding activates the
renin-angiotensin cascade and causes the translocation of Zbtb16 to
the nucleus, where Zbtb16 represses transcription of Atp6ap2
[25,26]. This is consistent with an increase in angiotensinergic
activity in the brain, resulting in increased Ang II formation [27]
accompanied by elevation in bindingof prorenin/renin to Atp6ap2.
Therefore the overexpression of Zbtb16 observed here during the
active phase might indicate that this gene is involved in a servo-
regulatory mechanism that, by inhibiting component(s) of the renin-
angiotensin system, could be attempting to bring BP back to normal
levels.
Arginine vasopressin (AVP, encoded by the gene Avp, and whose
mRNA showed an aFD of 2.3) and oxytocin (OXT; gene Oxt;
aFD=3.4) are evolutionarily-related hormones, AVP being a well-
known regulator of body water balance and thereby BP [28]. AVP
synthesis in the hypothalamus is increased by many stimuli, including
hyperosmolality [29], Ang II or a decrease in BP [28,30], although it
remains to be seen whether the BP reduction during the ‘trough’ of
circadian BP in the Schlager hypertensive mouse would be sufficient
to contribute to the rise in Avp expression. Microinjection of oxytocin
Figure 5. Top four molecular networks from the differentially expressed genes at ‘peak’ BP in the Schlager hypertensive mice,
showing an enrichment of genes for (A) cardiovascular disease and molecular transport, (B) metabolic disease, (C) cell morphology,
cellular assembly and organization, and (D) lipid metabolism, small molecule biochemistry and amino acid metabolism. The
networks were constructed using the Ingenuity Pathway Analysis (IPA, IngenuityH Systems, www.ingenuity.com) application. Genes over-expressed
in our gene list are represented by green and genes under-expressed by red.
doi:10.1371/journal.pone.0019203.g005
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deletion of the gene Avp leads to hypotension [32]. Both AVP and
OXT are co-localized with Atp6ap2 in the hypothalamus [33],
consistent with the possible involvement of a brain angiotensinergic
system in circadian BP regulation.
In support of our findings, overexpression of Trh (aFD=2.1)
leads to hypertension in normal rats [34]. In contrast, knocking
down this gene reduced BP in obesity-induced hypertensive rats
[35]. The effect of TRH on BP seems to be mediated by the effects
on sympathetic nerve activity [36].
We have demonstrated recently that Ccl19 (aFD=1.7) and Hcrt
(aFD=2.1) are differentially expressed in BPH/2J mice in early
and established phases of hypertension [37]. In the present study
we have now shown that these genes also contribute to the
exaggerated circadian BP differences in this mouse strain. The
overexpression of Ccl19 might increase inflammatory response by
attracting lymphocytes and dendritic cells [38]. The increase in
inflammation at ‘peak’ BP in the BPH/2J mouse is supported by
our GO and GST analyses, and the higher levels of inflammatory
markers that have been reported in hypertensive patients during
the morning BP surge [39].
Besides having a possible role in the onset and maintenance of
BP in hypertensive Schlager mice, Hcrt also seems to contribute to
the heightened stress response in this strain [37] and now in
circadian BP. Intracerebroventricular (i.c.v.) administration of
hypocretin, by acting on PVN neurons, increases mean arterial
pressure, heart rate and renal sympathetic nerve activity [40,41].
Hcrt knockout experiments showed that endogenous hypocretin
participates in BP maintenance [42], apparently by increasing
sympathetic outflow and consequent induction of the sympatho-
adrenomedullary system [42,43].
None of the 212 genes we identified here were clock genes,
highlighting the success of our statistical analysis in the elimination
of clock genes. Moreover our data analysis shows the potency of
the aFD statistics in microarray analysis, the latter being validated
by qPCR. In the case of Avp, Oxt and Trh, the aFD value measured
by qPCR was considerably larger than that generated by the
microarray analysis. Such findings are not unique [44] and most
likely represent differences between solid-state and solution
hybridization, coupled with use of the RMA algorithm, which
provides greater specificity and sensitivity, but blunts the
magnitude of the fold change [14].
The present study was facilitated by the large magnitude of the
circadian changes in BP characteristic of the genetic model of
hypertension studied. Other commonly used genetic models of
hypertension, such as the spontaneously hypertensive rat, would
be much less suitable because they show much smaller circadian
differences in BP [45]. Although the replication of our findings in
humans would be desirable, biopsy of hypothalamic tissue from
human subjects, especially at specific times of the diurnal cycle,
would present a challenge. Animal experiments in vivo will,
moreover, be necessary to discern whether the changes in
expression of these genes have a role in the circadian variation
in BP in the Schlager hypertensive mouse or if they merely reflect
secondary or coincidental phenomena that are not causally
influencing BP. Such investigations were beyond the scope of
the present study.
Although we sought to prevent clock genes from showing up in
our analysis, and no known clock genes were amongst the genes
we identified, we cannot absolutely rule out the possibility that
some of the genes found were ones not previously recognized as
having clock functions, and thus could nevertheless also be
contributing to the strain differences in circadian BP patterns
between the hypertensive and normotensive mice.
In conclusion, the present study has identified hypothalamic
gene signatures of exaggerated circadian BP changes in hyperten-
sion in the Schlager BPH/2J mouse, which displays a morning BP
surge similar to that seen in human essential hypertension. The
212 differentially expressed genes identified included Aldh1a2, Avp,
Ccl19, Hcrt, Oxt, Slc8a1, Trh and Zbtb16. The integration of
pathways involved in the neural and endocrine communication of
the hypothalamus with other tissues is highly complex, and much
remains to be elucidated. The particular genes revealed here were,
moreover, supported by a combination of validation by qPCR,
biological meaning and the use of robust statistical analyses with
stringent adjustments. Our findings should help guide further
research aimed at elucidation of the mechanisms involved in the
cause of circadian variation in BP in the Schlager hypertensive
mouse and, ultimately, in the morning BP surge in human
essential hypertension.
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